Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer

Importantly, the combination of giredestrant and everolimus was well tolerated

Metropolis Healthcare acquires Ambika Pathology Laboratory

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute

Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain

The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem

AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing

Novo Nordisk’s Wegovy delivered 16.6% weight loss

Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight

HCG Manavata launches awareness campaign for prostate cancer

Encouraging early detection and breaking the silence around men’s health

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program